0001562180-16-003208.txt : 20161004 0001562180-16-003208.hdr.sgml : 20161004 20161004161230 ACCESSION NUMBER: 0001562180-16-003208 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20161003 FILED AS OF DATE: 20161004 DATE AS OF CHANGE: 20161004 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Akebia Therapeutics, Inc. CENTRAL INDEX KEY: 0001517022 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 208756903 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 245 FIRST STREET STREET 2: SUITE 1100 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-871-2098 MAIL ADDRESS: STREET 1: 245 FIRST STREET STREET 2: SUITE 1100 CITY: CAMBRIDGE STATE: MA ZIP: 02142 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Nash Duane CENTRAL INDEX KEY: 0001591098 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36352 FILM NUMBER: 161918976 MAIL ADDRESS: STREET 1: C/O VITAL THERAPIES, INC. STREET 2: 15010 AVENUE OF SCIENCE, SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92128 4 1 primarydocument.xml PRIMARY DOCUMENT X0306 4 2016-10-03 false 0001517022 Akebia Therapeutics, Inc. AKBA 0001591098 Nash Duane C/O AKEBIA THERAPEUTICS, INC. 245 FIRST STREET CAMBRIDGE MA 02142 true false false false Common Stock 2016-10-03 4 S false 1981.00 8.9581 D 27648.00 D 47,525 shares of restricted stock (as adjusted from 27,157 shares prior to the 1.75-for-1 stock split effected on March 6, 2014) were awarded on December 23, 2013. Fifty percent of the shares vested on December 23, 2014. The remaining fifty percent vest ratably on the first day of each calendar quarter over three years from the first anniversary of the grant date until fully vested, assuming continued service through the applicable vesting date. Shares sold by reporting person pursuant to a 10b5-1 plan to pay taxes in connection with the vesting of restricted stock pursuant to the December 23, 2013 award described in footnote 1. The price reported in this Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.88 to $9.00, inclusive. The reporting person undertakes to provide Issuer, any security holder of Issuer, or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Nicole R. Hadas, Attorney-in-Fact for Duane Nash 2016-10-04